מוצרים ושירותים לניסויים קליניים

Bulk APIs

  • Custom packaging
  • Purity control
  • ISO / cGMP compliant manufacturing standards
  • Long-term supply contracts
  • Secured delivery facilitation
  • Available also in solid forms

 

 

API

Cannabinoid

CAS #

Purity

Description

CBD

Cannabidiol

13956-29-1

>99%

Cannabidiol is a non-psychoactive cannabinoid found in cannabis that has efficacy for a wide range of medical conditions including epilepsy, bipolar disorder, inflammation, and cancer.

CBG

Cannabigerol

25654-31-3

>99%

A non-psychoactive cannabinoid found in Cannabis, Cannabigerol (CBG) reportedly has efficacy for medical conditions such as glaucoma and inflammatory bowel disease.

CBC

Cannabichromene

20675-51-8

>98%

Cannabichromene (CBC) is a non-psychoactive cannabinoid of Cannabis that reportedly exerts anti-inflammatory, antimicrobial and analgesic activity.

CBN

Cannabinol

521-35-7

>99%

CBN is either non-psychoactive or very mildly psychoactive. Has sedative effect. Cannabinol reduces intra-ocular pressure in the eye so it can be used in the treatment of Glaucoma, Fights free radicals in the bloodstream, and it performs similarly to THC in pain reduction treatments.

CBDa

Cannabidiolic acid

1244-58-2

>99%

CBDa demonstrates anti-emetic (lessens vomit/nausea) and anti-proliferative effects. Also possesses anti-inflammatory properties

CBGa

Cannabigerolic acid

25555-57-1

>94%

A non-psychoactive cannabinoid, cannabigerolic acid (CBGA), is the precursor to THCA, CBDA, and CBCA cannabinoids in Cannabis. Cannabigerolic acid reportedly has efficacy in treatment of cancer and schizophrenia.

∆9-THC

Delta9-Tetrahydrocannabinol

1972-08-3

>99%

THC is responsible for a pain relieving effects such as neuropathic or nerve-related pain. Treats PTSD-related symptoms. Δ9-THC is the main active constituent and the primary psychoactive cannabinoid of cannabis. Besides persistent illicit use this drug is suitable as treatment for anorexia and nausea. Also acts as appetite stimulant. Uses in treatment of Glaucoma, Asthma and sleep disorders.

∆8-THC

Delta8-Tetrahydrocannabinol

5957-75-5

>99%

Delta-8-Tetrahydrocannabinol is an analogue of tetrahydrocannabinol (THC) with antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective properties.

∆9-THCa

Tetrahydrocannabinolic acid

 

23978-85-0

>96%

Δ9-THCA is non- psychoactive cannabinoid. Δ9-THCA possesses anti-inflammatory and anti-neurodegenerative properties. Suggested therapeutic properties for treatment of  arthritis, lupus, neurodegenerative diseases, nausea and appetite loss, prostate cancer.

THCV/THC-C3

Tetrahydrocannabivarin

31262-37-0

>98%

THCV is psychoactive cannabinoid.

THCV is an antagonist of the CB1 and CB2 receptors, and is being studied for its use as an appetite suppressant. potential aid in fighting obesity.

CONTACT US

Cannabinoid APIs for clinical trials

  • Per-spec dosage, mix, purity and packaging
  • FDA/cGMP grade production

CONTACT US

CRO Services

  • We provide support for companies developing cannabinoid pharmaceuticals
  • B.O.L Pharma has ample access to CRO facilities, top-tier hospitals collaborating on clinical studies and a wide range of relevant patients and trial participants as per indications tested

Testing & Analytics

  • We employ drug delivery technologies to optimize drug’s therapeutic value and maximize desired affect and efficacy
  • We provide testing services and analytical methods development to help with compliance of submission to regulatory agencies

CONTACT US

CONTACT US

 שאיפה לחיים, כל הזכויות שמורות 2016©